Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
iX Biopharma Ltd. ( (SG:42C) ) just unveiled an announcement.
iX Biopharma has granted 9,400,892 ordinary shares under its iX Performance Share Plan to employees, excluding the chairman and CEO, as part of an equity-based incentive program. The awards, priced at S$0.41 per share based on the market close on May 8, 2026, involve no consideration payable by recipients and are intended to align employee interests with long-term shareholder value.
The share awards will vest in four tranches, with 2,955,853 shares vesting immediately on the grant date, followed by additional vesting on February 28, 2027, May 8, 2027, and February 29, 2028. The move underscores the company’s use of performance-based equity compensation to retain and motivate staff, while signaling a commitment to structured long-term incentive schemes in line with Catalist rules and broader market practices.
The most recent analyst rating on (SG:42C) stock is a Buy with a S$1.00 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.
More about iX Biopharma Ltd.
iX Biopharma Ltd. is a Singapore-incorporated biopharmaceutical company listed on the Catalist board of the Singapore Exchange. The group focuses on developing and commercializing pharmaceutical and related healthcare products, operating through its subsidiaries to serve healthcare and therapeutic markets.
Average Trading Volume: 19,533,506
Technical Sentiment Signal: Buy
Current Market Cap: S$430.8M
Learn more about 42C stock on TipRanks’ Stock Analysis page.